CompaniesCANbridge Life Sciences

CANbridge Life Sciences

defunct
About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

4

As Collaborator

0

Total Enrollment

249

By Phase

PHASE2: 2PHASE1: 1

By Status

UNKNOWN: 3COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
NCT02853565
NCT03746288
NCT05447195
Hover over trial bars to see details

Recent Trials

NCT05447195Lead Sponsor
Phase 2 Study of CAN008 in Subjects With GBM
PHASE2Unknown
117 participants
Started: Oct 10, 2021 · Completed: Aug 31, 2024
NCT03746288Lead Sponsor
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
PHASE2Unknown
60 participants
Started: Nov 20, 2018 · Completed: Dec 31, 2021
NCT03152708Lead Sponsor
CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma
N/AUnknown
62 participants
Started: Nov 1, 2017 · Completed: Dec 31, 2017
NCT02853565Lead Sponsor
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
PHASE1Completed
10 participants
Started: Aug 31, 2016 · Completed: Sep 30, 2018